Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO-3021 in CLDN18.2-expressing gastric/GEJ adenocarcinoma
NCT05980416Phase 1Terminated
- Sponsor
- Elevation Oncology, Inc.
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of SYSA1801 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Elevation Oncology, Inc. Primary endpoints: Treatment Emergent Adverse Events at 12 months, Dose Limiting Toxicities at 21 days and 4 more. Started Aug 2023; status: terminated.
02
Drugs
SYSA1801
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05980416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980416.